Value of Improved Mayo Endoscopic Score for evaluating treatment efficacy for active ulcerative colitis / 南方医科大学学报

OBJECTIVE@#To assess the value of Improved Mayo Endoscopic Score (IMES) for evaluation of treatment efficacy for active ulcerative colitis (UC).@*METHODS@#We retrospectively analyzed the clinical and endoscopic data of 103 patients diagnosed with active UC in Beijing Tsinghua Changgung Hospital from January, 2015 to December, 2020. The severity of endoscopic lesions was determined by Mayo Endoscopic Score and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and the area of the endoscopic lesions was evaluated based on the Montreal classification system. The IMES was established by combining the MES with the Montreal classification.@*RESULTS@#Univariate analysis suggested that young patients (<40 years old), patients with extensive disease type (E3), patients with high endoscopic scores (MES=3, UCEIS>4, and IMES>4), and patients receiving advanced drug therapy (with systemic hormones, immunosuppressants, immunomodulators, and biological agents, etc.) had lower clinical and endoscopic remission rates. COX survival analysis showed that IMES≤4 was an independent risk factor for clinical and endoscopic remission. ROC curve indicated that the predictive value of IMSE≤4 for clinical and endoscopic remission (AUC=0.7793 and 0.7095, respectively; P<0.01) was better than that of Montreal (AUC=0.7357 and 0.6847, respectively; P<0.01), MES=2 (AUC=0.6671 and 0.5929, respectively; P<0.01), and UCEIS≤4 (AUC=0.6823 and 0.6459, respectively; P<0.01); IMES=5 had a better predictive value for patients with active UC undergoing colectomy tham E3 and MES=3.@*CONCLUSION@#IMES has good value in evaluating treatment efficacy for active UC.

Effect of trastuzumab combined with endocrine therapy on hormone receptor and human epidermal growth factor receptor-2 positive advanced breast cancer / 中国基层医药

Objective@#To investigate the effect of trastuzumab combined with endocrine therapy on hormone receptor (HR) and human epidermal growth factor receptor-2 (HER-2) positive advanced breast cancer.@*Methods@#From January 2001 to March 2017, 88 patients with HR and HER-2 positive advanced breast cancer were selected.The patients were divided into two groups according to the random number method, with 44 cases in each group.All the patients were treated with routine chemotherapy, radiotherapy and biology therapy.The control group was treated with tamoxifen, and the observation group was treated with trastuzumab on the basis of the control group.All the patients were followed up for 6 months.The changes of serum E2 and quality of life were compared before and after intervention.The clinical effects of the two groups were compared.@*Results@#The serum E2 of the observation group was (15.3±0.5)pmol/L, which was lower than that before intervention [(65.4±2.0)pmol/L]and that of the control group after treatment [(36.9±1.9)pmol/L](t=70.109, 0.240, all P<0.05). After the intervention, the quality of life score of the observation group was (35.3±1.1)points, which was higher than that before intervention[(81.5±2.3)points]and that of the control group after treatment [(56.6±1.7)points](t=114.608, 66.530, all P<0.05). The effective rate of the observation group was 31.8%, which was higher than 9.1% of the control group (χ2=5.657, P<0.05).@*Conclusion@#Trastuzumab combined with endocrine maintenance therapy can effectively regulate the endocrine level of patients with HR and HER-2 positive advanced breast cancer, improve the quality of life and clinical therapeutic effect.